BD
Black Diamond Therapeutics
MA - Cambridge
BiotechnologyFocus: Targeting allosteric mutant oncogenes
Black Diamond Therapeutics is a life sciences company focused on Targeting allosteric mutant oncogenes.
Oncology
Open Jobs
0
Pipeline & Clinical Trials
BDTX-189
Solid TumorClinical Trials (1)
NCT04209465A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Phase 1Azathioprine 50Mg Tab
Therapeutic EquivalencyClinical Trials (1)
NCT03930264Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)
Phase 1silevertinib
Non-Small Cell Lung CancerClinical Trials (1)
NCT05256290Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Phase 1/2silevertinib in combination with temozolomide
Glioblastoma (GBM)Clinical Trials (1)
NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 4 clinical trials
Hiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles